Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IntelliPharmaCeutics International's enterprise value is $0.00 Mil.
IntelliPharmaCeutics International's EBITDA for the trailing twelve months (TTM) ended in Aug. 2023 was $-2.71 Mil. Therefore, IntelliPharmaCeutics International's EV-to-EBITDA for today is 0.00.
IPCIQ's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 14.49 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
IntelliPharmaCeutics International (OTCPK:IPCIQ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IntelliPharmaCeutics International's PE Ratio (TTM) for today is calculated as:
IntelliPharmaCeutics International's share price for today is $0.15.
IntelliPharmaCeutics International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.092.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IntelliPharmaCeutics International EV-to-EBITDA Chart
IPCIQ vs CHRO, KTTA, FRTX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, IntelliPharmaCeutics International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IntelliPharmaCeutics International EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IntelliPharmaCeutics International's EV-to-EBITDA falls into.
IntelliPharmaCeutics International's current Enterprise Value is $0.00 Mil.
IntelliPharmaCeutics International's EBITDA for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IntelliPharmaCeutics International (IPCIQ) has a EV-to-EBITDA of 0.00 as of Aug. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IntelliPharmaCeutics International.
Is IntelliPharmaCeutics International's EV-to-EBITDA too high?
IntelliPharmaCeutics International's current EV-to-EBITDA is 0.00. Overall, IntelliPharmaCeutics International has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does IntelliPharmaCeutics International's EV-to-EBITDA compare to CHRO and KTTA?
IntelliPharmaCeutics International's EV-to-EBITDA of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 14.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.49, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IntelliPharmaCeutics International. For the Biotechnology industry, the median EV-to-EBITDA is 14.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IntelliPharmaCeutics International's current EV-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IntelliPharmaCeutics International stock overvalued right now?
IntelliPharmaCeutics International (IPCIQ) has a current EV-to-EBITDA of 0.00. The current EV-to-EBITDA is 0.00. IntelliPharmaCeutics International's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For IntelliPharmaCeutics International (IPCIQ), the current EV-to-EBITDA is 0.00 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline.
16GF Score
Get the complete analysis for IPCIQ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPCIQ has been successfully added to your 
